Aclaris Therapeutics, Inc.
Extract: Bylaws Amended/Restated (Plain English Desc) from a 8-K on 06/24/2020   Download
SEC Document
SEC Filing

On and effective June 23, 2020, the Board of Directors of Aclaris Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s Amended and Restated Bylaws (the “Bylaws”), to adopt a new Article XV, Section 47, Federal Forum Selection. Section 47 provides that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, and that any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Company shall be deemed to have notice of and consented to the federal forum selection provision.